Stevens P E, Riley B, Davies S P, Gower P E, Brown E A, Kox W
Department of Medicine, Charing Cross Hospital, London.
Lancet. 1988 Jul 16;2(8603):150-2. doi: 10.1016/s0140-6736(88)90695-2.
Continuous arteriovenous haemodialysis (CAVHD) is a new treatment for critically ill patients with renal failure that combines convective and diffusive solute removal. The clearance of urea (14.8-22.1 ml/min) is sufficient to achieve a steady-state urea concentration of 22 mmol/l, even in patients with a high catabolic rate and cardiovascular instability. The technique is simple and does not involve the use of blood pumps or specialised staff. Initial experience in 36 critically ill patients with renal failure indicates that it is safe and reliable, with less associated morbidity than other techniques.
连续性动静脉血液透析(CAVHD)是一种针对重症肾衰竭患者的新治疗方法,它结合了对流和扩散溶质清除。尿素清除率(14.8 - 22.1毫升/分钟)足以使尿素浓度达到22毫摩尔/升的稳态,即使是在分解代谢率高和心血管不稳定的患者中也是如此。该技术简单,不涉及使用血泵或专业人员。对36例重症肾衰竭患者的初步经验表明,它安全可靠,与其他技术相比相关发病率更低。